Department of Surgery, Boston Medical Center, Boston University School of Medicine, Boston, MD, USA.
Division of Surgical Oncology, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ann Surg Oncol. 2022 Apr;29(4):2444-2451. doi: 10.1245/s10434-021-11196-3. Epub 2022 Jan 7.
The volume-outcome relationship has been well-established for pancreaticoduodenectomy (PD). It remains unclear if this is primarily driven by hospital volume or individual surgeon experience.
This study aimed to determine the relationship of hospital and surgeon volume on short-term outcomes of patients with pancreatic adenocarcinoma undergoing PD.
Patients >65 years of age who underwent PD for pancreatic adenocarcinoma were identified from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database (2008-2015). Analyses were stratified by hospital volume and then surgeon volume, creating four volume cohorts: low-low (low hospital, low surgeon), low-high (low hospital, high surgeon), high-low (high hospital, low surgeon), high-high (high hospital, high surgeon). Propensity scores were created for the odds of undergoing surgery with high-volume surgeons. Following matching, multivariable analysis was used to assess the impact of surgeon volume on outcomes within each hospital volume cohort.
In total, 2450 patients were identified: 54.3% were treated at high-volume hospitals (27.0% low-volume surgeons, 73.0% high-volume surgeons) and 45.7% were treated at low-volume hospitals (76.9% low-volume surgeons, 23.1% high-volume surgeons). On matched multivariable analysis, there were no significant differences in the risk of major complications, 90-day mortality, and 30-day readmission based on surgeon volume within the low and high hospital volume cohorts.
Compared with surgeon volume, hospital volume is a more significant factor in predicting short-term outcomes after PD. This suggests that a focus on resources and care pathways, in combination with volume metrics, is more likely to achieve high-quality care for patients undergoing PD across all hospitals.
胰腺十二指肠切除术(PD)的量效关系已经得到充分证实。目前尚不清楚这主要是由医院量还是个别外科医生的经验驱动。
本研究旨在确定医院和外科医生量对接受 PD 的胰腺腺癌患者短期结局的关系。
从监测、流行病学和最终结果(SEER)-医疗保险数据库(2008-2015 年)中确定 65 岁以上接受 PD 治疗胰腺腺癌的患者。分析按医院量分层,然后按外科医生量分层,创建四个量值队列:低-低(低医院,低外科医生)、低-高(低医院,高外科医生)、高-低(高医院,低外科医生)、高-高(高医院,高外科医生)。为接受高量值外科医生手术的可能性创建倾向评分。匹配后,使用多变量分析评估外科医生量值对每个医院量值队列中结局的影响。
共确定 2450 例患者:54.3%在高量值医院接受治疗(27.0%低量值外科医生,73.0%高量值外科医生),45.7%在低量值医院接受治疗(76.9%低量值外科医生,23.1%高量值外科医生)。在匹配的多变量分析中,在低和高医院量值队列中,根据外科医生量值,在主要并发症、90 天死亡率和 30 天再入院风险方面无显著差异。
与外科医生量相比,医院量是预测 PD 后短期结局的更重要因素。这表明,关注资源和护理途径,结合量值指标,更有可能为所有医院接受 PD 的患者提供高质量的护理。